SCHEMBL6023835

SCHEMBL6023835

O=C(O)/C=C/c1cc(Cl)c(O)c(Cl)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 3/20 0.55
PTGS1 P23219 1/20 0.55
PTGS2 P35354 1/20 0.55
KDM4E B2RXH2 6/20 0.50
AKR1B10 O60218 3/20 0.50
AKR1B1 P15121 3/20 0.50
HSD17B10 Q99714 3/20 0.50
CA12 O43570 3/20 0.50
CA1 P00915 3/20 0.50
CA2 P00918 3/20 0.50
CA3 P07451 3/20 0.50
CA4 P22748 3/20 0.50
CA6 P23280 3/20 0.50
CA5A P35218 3/20 0.50
CA7 P43166 3/20 0.50
CA9 Q16790 3/20 0.50
CA14 Q9ULX7 3/20 0.50
CA5B Q9Y2D0 3/20 0.50
DPP4 P27487 2/20 0.50
MMP2 P08253 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6023839 1.00 PKM (0.55) PKMPTGS1PTGS2KDM4EAKR1B10
SCHEMBL7163064 0.85 CYP1A2 (0.59) HSD17B10TTRALDH1A1CYP3A4CYP2C9
SCHEMBL6852840 0.85 CYP1A2 (0.59) HSD17B10TTRALDH1A1CYP3A4CYP2C9
SCHEMBL22154435 0.80 ITGB2 (0.47) PKMPTGS1PTGS2KDM4EAKR1B10
SCHEMBL8746675 0.79 HCAR2 (0.64) PKMPTGS1PTGS2KDM4EAKR1B10
SCHEMBL8746677 0.79 HCAR2 (0.64) PKMPTGS1PTGS2KDM4EAKR1B10
SCHEMBL7160152 0.79 GSR (0.50) HSD17B10TTRALDH1A1CYP3A4CYP2C9
SCHEMBL7160153 0.79 GSR (0.50) HSD17B10TTRALDH1A1CYP3A4CYP2C9
SCHEMBL6022866 0.79 KDM4E (0.70) PKMPTGS1PTGS2KDM4EAKR1B10
SCHEMBL6022871 0.79 KDM4E (0.70) PKMPTGS1PTGS2KDM4EAKR1B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7053071-B2 For therapy of leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells THE BURNHAM INSTITUTE (US) 2006-05-30 US disclosed
EP-1456165-A1 INDUCTION OF APOPTOSIS IN CANCER CELLS The Burnham Institute (US) 2004-09-15 EP disclosed
US-20030176506-A1 Induction of apoptosis in cancer cells BURNHAM INSTITUTE FOR MEDICAL RESEARCH 2003-09-18 US disclosed
WO-2003048101-A1 INDUCTION OF APOPTOSIS IN CANCER CELLS THE BURNHAM INSTITUTE (US) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176506-A1 Induction of apoptosis in cancer cells MCL1, BAD, BCL2 PKM 3903/4885PTGS1 202/4885PTGS2 298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.